NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Prothena Corp. Public Ltd. Co. PRTA
15 fiscal years on record · USD · FY2025 reported · SEC filings only
$-244.1M
In brief
What this company does
Written from the business description in Prothena Corporation plc's annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.
Growth
USD 9.7M
Revenue, FY2025 · full 15-year series below
Revenue $M
Net income $M
FY2025 · Revenue 9.7 · Net income -244.1
Compound annual growth
Revenue compounded at +62.6% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−2521 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -2216.4% · Net -2520.6%
ROE
FY2025 · ROE -63.6%
Each USD of equity lost 64 cents this year.
The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.1 | 0.1 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | · |
| Operating income $B | −0.2 | −0.2 | −0.2 | −0.1 | 0.1 | −0.1 | −0.1 | −0.2 | −0.2 | −0.2 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.2 | −0.2 | −0.2 | −0.1 | 0.1 | −0.1 | −0.1 | −0.2 | −0.2 | −0.2 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.2 | −0.1 | −0.1 | −0.1 | 0.1 | −0.1 | −0.1 | −0.2 | −0.2 | −0.2 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −4.53 | −2.27 | −2.76 | −2.47 | 1.38 | −2.78 | −1.95 | −3.93 | −4.07 | −4.66 | −2.66 | −0.29 | −2.20 | −2.84 | −2.05 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −63.6 | −23.3 | −24.8 | −21.5 | 20.6 | −48.6 | −26.1 | −42.6 | −39.7 | −44.1 | −24.8 | −3.1 | −27.4 | −32.7 | · |
| Shares out B | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 58 reconciliationsAUDITED
Reconciled in 15 of 19 fiscal years. 18 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L2
Fiscal year endsDecember 31
Data on record since2011